Introduced by Assembly Member Negrete McLeod

February 21, 2003

An act to amend Section 14105.45 of the Welfare and Institutions Code, relating to Medi-Cal.

LEGISLATIVE COUNSEL'S DIGEST

AB 1122, as introduced, Negrete McLeod. Pharmaceutical drugs: reimbursement: report to Legislature.

Existing law establishes the Medi-Cal program, administered by the State Department of Health Services, which provides qualified low-income persons with health care services, including prescription drugs.

Under existing law, the department is considered to be the purchaser of prescribed drugs under the Medi-Cal program, and is authorized to enter into contracts with manufacturers of prescription drugs, as specified.

Existing law requires the department to establish a list of Maximum Allowable Ingredient Costs (MAIC) for drugs based on reference to certain drug brands, to publish that list in Medi-Cal provider bulletins, and to update MAICs at least every two months.

This bill would require the department to report to the Legislature, by July 1, 2004, on the implementation of the requirements for the list of MAIC for prescription drugs.

Vote: majority. Appropriation: no. Fiscal committee: yes. State-mandated local program: no.

AB 1122 — 2 —

The people of the State of California do enact as follows:

SECTION 1. Section 14105.45 of the Welfare and Institutions Code is amended to read:

- 14105.45. (a) The department shall establish a list of Maximum Allowable Ingredient Costs (MAIC) for drugs, which shall be published in provider bulletins. On the effective date of this section, MAICS MAICs listed in Title 22 of the California Code of Regulations shall be included in the list of MAICS. MAICS MAICS shall no longer be listed in regulations. The department shall repeal Section 51513.3 of Title 22 of the California Code of Regulations.
 - (b) The department shall update existing MAICS MAICS and establish additional MAICS MAICS in accordance with all of the following:
 - (1) The department shall base an MAIC on the mean of the wholesale selling prices of drugs generically equivalent to the innovator brand that are available in California from selected major wholesale drug distributors. For the purposes of this section, "wholesale selling price" means the price, including discounts and rebates, paid by a pharmacy to a wholesale drug distributor for a drug.
 - (2) The decision regarding therapeutic equivalency shall be based on the federal Food and Drug Administration determinations. For antacid drugs, therapeutic equivalency shall be determined by the department based on review of in vitro scientific data.
 - (3) The department shall request information from drug manufacturers regarding the availability of their products throughout the state to outpatient pharmacies through the usual and customary distribution channels in sufficient quantities to meet the needs of the Medi-Cal program.
 - (4) The department shall update MAICS MAICs at least every two months and notify Medi-Cal providers at least 30 days prior to the effective date of an MAIC.
 - (c) The department shall report to the Legislature by July 1, 2004, on the implementation of the requirements of this section regarding the list of MAICs for drugs.
 - (d) Notwithstanding the provisions of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title

—3— **AB 1122**

- 2 of the Government Code, actions under this section shan not be
 subject to the Administrative Procedure Act, or to the review and
 approval of the Office of Administrative Law.